

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts TROPION-Lung02

- Datopotamab deruxtecan (Dato-DXd), a TROP2 targeting antibody drug conjugate, in combination with pembrolizumab with or without chemotherapy, provides clinically meaningful benefit (response rate, progression-free survival, treatment durability) in patients with metastatic non-small cell lung cancer, including patients who were previously untreated (treatment naïve)
- Adverse events of special interest with datopotamab deruxtecan include ocular toxicities, interstitial lung disease, and stomatitis. Appropriate awareness, prevention, and management of these unique toxicities is of increased importance as Dato-DXd is integrated into frontline treatment strategies to ensure patients remain on therapy and maintain quality of life